Fibrinolysis


Also found in: Dictionary, Thesaurus, Medical, Wikipedia.

fibrinolysis

[‚fī·brə′näl·ə·səs]
(physiology)
Liquefaction of coagulated blood by the action of plasmin on fibrin.
McGraw-Hill Dictionary of Scientific & Technical Terms, 6E, Copyright © 2003 by The McGraw-Hill Companies, Inc.
The following article is from The Great Soviet Encyclopedia (1979). It might be outdated or ideologically biased.

Fibrinolysis

 

the dissolution of intravascular thrombi and extravascular deposits of fibrin by the enzyme fibrinolysin. Fibrinolysis is important for keeping the blood liquid and the blood vessels and glandular ducts patent. The term was proposed by the French physiologist A. Dastre in 1893.

Uncoagulated blood was first discovered in the blood vessels of persons who died suddenly by the Italian physician G. Morgagni (1769) and the Scotch anatomist J. Hunter (1794). In 1906 the German researcher P. Morawitz showed that such blood lacks fibrinogen and fibrin. He attributed the absence of these proteins in plasma to the action of a specific enzyme. The enzymatic nature of fibrinolysis was demonstrated by the Soviet scientist V. S. Il’in between 1948 and 1955.

The fibrinolysis system consists of four components: profibrinolysin (or plasminogen), fibrinolysin (or plasmin), profibrinolysin activators, and fibrinolysin inhibitors. Profibrinolysin is converted in the body by the action of enzymatic activators (plasma and tissue activators and urokinase) to fibrinolysin, which under normal physiological conditions is bound by inhibitors—antiplasmins. In certain pathological conditions—thromboses—caused by the breakdown of the clotting mechanism, the bond with the antiplasmins is broken, and fibrinolysin hydrolyzes the fibrin of thrombi. Normally, the activity of the fibrinolysis enzymatic system in the body is low. In the presence of stress, during physical exertion, or after the injection of adrenaline, it may increase sharply. The formation of excessive fibrinolysin by the release of large quantities of tissue activator, resulting from changes in the permeability of blood vessels or injury to them, produces extreme activation of fibrinolysis, which causes bleeding, for example, during obstetrical complications, in cirrhosis of the liver, and during transfusions of incompatible blood. Bleeding is arrested by injection of artificial fibrinolysin inhibitors. A decrease in activity of the fibrinolysis system is associated with the development of atherosclerosis and thromboembolic complications. In such conditions, fibrinolysis is used for thrombolytic therapy.

REFERENCES

Andreenko, G. V. Fibrinoliz: Khimiia i fiziologiia protsessa. Moscow, 1967.
Andreenko, G. V. “Sovremennye predstavleniia o sistemakh gemostaza i fibrinoliza.” Klinicheskaia meditsina, 1974, vol. 52.
Kudriashov, B. A. Biologicheskie problemy reguliatsii zhidkogo sostoianiia krovi i ee svertyvaniia. Moscow, 1975.
Astedt, B. “On Fibrinolysis.” Acta Obstetricia et Gynecologica Scandinavica, 1972, no. 51, suppl. 18.
Rickli, E. E. “Human Plasminogen: A Summary of Studies on Its Isolation, Characterization and Activation Mechanism.” Immunochemistry, 1975, vol. 12, nos. 6–7.

G. V. ANDREENKO

The Great Soviet Encyclopedia, 3rd Edition (1970-1979). © 2010 The Gale Group, Inc. All rights reserved.
Mentioned in ?
References in periodicals archive ?
A Prospective Single-Arm, Multicenter Trial of Ultrasound-Facilitated Catheter-Directed, Low-Dose Fibrinolysis for Acute Massive and Sub-massive Pulmonary Embolism: SEATTLE II Study.
The following loss of the balance between fibrinolysis and coagulation might finally contribute to vessel engulfment with fibrin and breakdown of vessel patency, symptomatic of a tendency to the development of thrombotic complications in this particular autoimmune disorder.4 D-dimer is the heterogeneous class of end stage degradation products that directly reflect the level of lysed cross-linked fibrin, occurring in vivo with a wide range of molecular weights.
The Food and Drug Administration has approved t-PA (alteplase) 100 mg administered as a continuous infusion over 2 hours for the fibrinolysis of massive PE.
In addition, TAFI may play a key role in regulating the crosstalk between coagulation, fibrinolysis, and inflammation.
VerstraeteM.Clinical application of inhibitors of fibrinolysis. Drugs.
However, there is very limited data to date comparing all these fibrinolysis biomarkers simultaneously in subjects with MS, simple central obesity without Metabolic Syndrome (COB) and normal controls (NC).
Fibrinolysis may be considered in a young patient (without usual contraindications) who arrives with strong chest pain consistent with acute coronary occlusion, less than 3 hours of symptoms, and with convincing de Winter T-wave ECG pattern (especially if a prior baseline ECG is available for comparison) for a rural non-PCI hospital far away from PCI capable hospital.
Since FGA Arg35 is part of the thrombin cleavage site at the N-terminal end of the fibrinogen A [alpha] chain, mutation at this site was predicted to result in delayed or absent fibrin peptide A release and subsequent prolonged polymerization.10,11 Besides, there are also studies reported that FGA Arg35 mutation might affect strength of fibrin network12, induce fibrinolysis resistance13, or decrease platelet aggregation support.14 All the speculated possible function mutation related with FGA Arg35 mutation are reasonably related to a clinical manifestation of bleeding discrepancy.
Ferrant et al., "Management of pregnancy in paroxysmal nocturnal hemoglobinuria on long-term eculizumab," Blood Coagulation and Fibrinolysis, vol.
This difference is associated with fibrinolysis ([beta] = 0.41 [+ or -] 0.10, 95% = CI = 0.21-0.62, p < 0.001), which was performed in ischemic patients if the hospital arrival time was soon after stroke onset.
To overcome the limitations associated with animal models and static in vitro assays for assessing fibrinolysis, Hosokawa et al.